Brief: Datroway Plus Rilvegostomig Showed Promising Tumor Responses In Tropion-Pantumor03 Phase 2 Trial

Daiichi Sankyo

17/10/2025 15:08

Oct 17 (Reuters) - Daiichi Sankyo Co Ltd 4568.T:

DATROWAY® PLUS RILVEGOSTOMIG SHOWED PROMISING TUMOR RESPONSES IN PATIENTS WITH METASTATIC UROTHELIAL CANCER IN TROPION-PANTUMOR03 PHASE 2 TRIAL

DAIICHI SANKYO CO LTD - DATROWAY PLUS RILVEGOSTOMIG SHOWS 68.2% RESPONSE RATE

DAIICHI SANKYO CO LTD - DATROWAY PLUS RILVEGOSTOMIG SAFETY PROFILE CONSISTENT

Source text: ID:nBw7rSFMBa

Further company coverage: 4568.T